91勛圖

Liquid Biopsy-Driven Early Detection of Esophageal and Colorectal Cancers via Circulating Tumor DNA Methylation Signatures

Dr. Haruto Nakamura^*

Department of Medical Genomics, National Cancer Center Research Institute, Japan

Received Date: Mar 01, 2025 / Accepted Date: Mar 31, 2025 / Published Date: Mar 31, 2025

Citation: Haruto N (2025) Liquid Biopsy-Driven Early Detection of Esophageal andColorectal Cancers via Circulating Tumor DNA Methylation Signatures. J CancerDiagn 9: 288.

Copyright: 穢 2025 Haruto N. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited

To read the full article Peer-reviewed Article PDF

Esophageal and colorectal cancers (EC and CRC) represent major global health burdens with high mortality rates, primarily due to late-stage diagnoses. Conventional diagnostic methods, including endoscopy and colonoscopy, are invasive, costly, and limited in their ability to detect early-stage disease. Liquid biopsy, particularly the analysis of circulating tumor DNA (ctDNA), has emerged as a promising, non-invasive diagnostic tool for early cancer detection. Among various molecular features of ctDNA, DNA methylation signatures offer high specificity and sensitivity in identifying tumor-derived signals. This article explores the recent advances in ctDNA methylation profiling for the early detection of EC and CRC, highlighting its clinical relevance, technological platforms, biomarker development, and future applications in precision oncology